Modus Therapeutics reports on preclinical data on sevuparin in CKD with anemia presented at EHA2026

MODTXLehdistötiedote16.06.2026 klo 12.15

Stockholm, 16 June 2026 – Modus Therapeutics Holding AB (“Modus” or the “Company”) reports on preclinical data on sevuparin in chronic kidney disease (CKD) with anemia, presented at the European Hematology Association Congress 2026 (EHA2026) in Stockholm on 13 June 2026 by Dr. Michela Asperti.

The poster, titled “Therapeutic potential of sevuparin in chronic kidney disease anaemia: synergistic effects with EPO and molecular insights into renal protection” (PS2400), summarized preclinical data characterizing the mechanism of action of sevuparin in CKD with anemia. The work was conducted in collaboration with researchers at the University of Brescia, an academic partnership that has supported Modus' preclinical and translational program since 2018.

Among the observations presented, the data showed measurable effects of sevuparin on anemia in mice with CKD, both as monotherapy and in combination with EPO. The poster also reported that treatment with sevuparin modified the expression of molecular markers of relevance for the pathogenesis of chronic kidney disease. Together, these observations contribute to the characterization of sevuparin's mechanisms of action in this model of chronic kidney disease with anemia.

“The data presented at EHA2026 add valuable insights into how sevuparin may act in CKD with anemia and reinforce the biological foundation of our ongoing clinical development. We look forward to building on this with a separate oral presentation at the European Iron Club Annual Meeting on 20 June 2026. We are grateful to the team at the University of Brescia for their continued contribution to this program,” said John Öhd, CEO of Modus Therapeutics.

The data presented at EHA2026 complement the broader characterization work supporting Modus' clinical development of sevuparin in CKD with anemia, including the ongoing Phase IIa study in patients with non-dialysis CKD and anemia.

Presentation details

Abstract code: PS2400
Title: Therapeutic potential of sevuparin in chronic kidney disease anaemia: synergistic effects with EPO and molecular insights into renal protection
Presenting author: Dr. Michela Asperti, University of Brescia
Format: Poster presentation, Session 2, 13 June 2026, Stockholmsmässan, Stockholm

The abstract was published through EHA's official channels and in HemaSphere, the official journal of EHA. The poster will be available through the EHA Library following the congress.

About Modus Therapeutics and sevuparin
Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.